ArticleJournal of neurology2026
Progressive disability but survival advantage in anti-Hu/ANNA1 paraneoplastic neurological syndromes.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 1 antineuronal nuclear or "Hu" antibody (ANNA1/Hu-IgG) is associated with paraneoplastic neurological syndromes (PNS), and most often, small cell lung carcinoma (SCLC).
objectivesTo evaluate factors associated with disability and survival in ANNA1/Hu-IgG PNS and to compare the survival of patients with SCLC (with and without ANNA1/Hu-IgG PNS).
methodsThis was a single-center cohort study of 45 patients with ANNA1/Hu-IgG PNS. Kaplan-Meier methods were used to estimate time to mortality, wheelchair dependence, and modified Rankin Scale (mRS) score > 2. Cox proportional hazards models and logistic regression were used to estimate hazard ratios (HRs) and odds ratios (ORs), respectively. Secondary analyses compared patients with ANNA1/Hu-IgG PNS to a cohort with SCLC. Survival was evaluated using Cox proportional hazards models, adjusting for age, sex, cancer stage, and treatment.
resultsDisability and survival were associated with clinical phenotype at onset, with limbic encephalitis having a greater hazard of mRS > 2 (HR = 6.84, 95% CI = 2.12-22.04, P = 0.001) and greater odds of death (HR = 2.44, 95% CI = 1.05-5.66, P = 0.039). Among patients with SCLC, the patients with ANNA1/Hu-IgG PNS + SCLC (n = 26) compared to SCLC-only (n = 1513) had a 41% lower hazard of death, adjusting for age, sex, stage, and cancer treatment (HR = 0.59, 95% CI = 0.37-0.96, P = 0.033).
conclusionIn ANNA1/Hu-IgG PNS, faster progression of disability and greater risk of mortality is associated with limbic encephalitis at onset, suggesting a potentially modifiable factor for early intervention. Patients with SCLC and ANNA1/Hu-IgG PNS survived longer than patients with SCLC without PNS, suggesting a survival advantage of paraneoplastic autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.